The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus

被引:0
|
作者
Parlar, Mehmet Akif [1 ]
Mutlu, Hakan [1 ]
Dogantekin, Betul [1 ]
Musaoglu, Ismail Serhat [1 ]
Albayrakoglu, Nisa Demirbosnak [1 ]
Yavuz, Mustafa Lutfi [2 ]
Ozbolat, Zehra Busra [3 ]
Kaplan, Mustafa [1 ]
机构
[1] Univ Hlth Sci, Sultan Abdulhamid Han Training & Res Hosp 2, Dept Internal Med, Tibbiye St, TR-34668 Istanbul, Turkiye
[2] Istanbul Univ, Fac Med, Dept Cardiol, TR-34093 Istanbul, Turkiye
[3] Cerkezkoy State Hosp, Dept Chest Dis, Tekirdag Prov Hlth Directorate, TR-59100 Tekirdag, Turkiye
关键词
diabetes mellitus; fatty pancreas; fatty liver; statin; steatosis; ADIPOSE-TISSUE INFLAMMATION; INSULIN-SECRETION; GLUCOLIPOTOXICITY; CHOLESTEROL; DYSFUNCTION; DISEASE; ATORVASTATIN; SIMVASTATIN; STEATOSIS; EFFICACY;
D O I
10.3390/diagnostics15040426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic beta-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. Methods: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. Results: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, p = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, p = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, p = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (beta +/- SE = -0.16 +/- 0.05, p = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (beta +/- SE = -0.16 +/- 0.07, p = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (beta +/- SE = 0.17 +/- 0.06, p = 0.011) and pitavastatin (beta +/- SE = 0.19 +/- 0.07, p = 0.008) were independently associated with an increase in log(PFF). Conclusions: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Statin Efficacy in Type 1 and Type 2 Diabetes Mellitus
    Ciriacks, Kevin
    Krishnaswami, Shanthi
    Patel, Shailendra
    Kidambi, Srividya
    DIABETES, 2013, 62 : A165 - A165
  • [12] Pancreatic fat fraction in dual-energy computed tomography as a potential quantitative parameter in the detection of type 2 diabetes mellitus
    Huang, Shiqi
    Liang, Yuhong
    Zhong, Xixi
    Luo, Qunzhi
    Yao, Xinqun
    Nong, Zhuo
    Luo, Yi
    Luo, Lian
    Jiang, Wei
    Qin, Xiangyun
    Lv, Yaping
    EUROPEAN JOURNAL OF RADIOLOGY, 2023, 159
  • [13] Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes
    Brindisi, Marie-Claude
    Guiu, Boris
    Duvillard, Laurence
    Athias, Anne
    Rollot, Fabien
    Bouillet, Benjamin
    Beacco, Maud
    Hillon, Patrick
    Cercueil, Jean-Pierre
    Verges, Bruno
    Petit, Jean-Michel
    ATHEROSCLEROSIS, 2012, 224 (02) : 465 - 468
  • [14] Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus
    Borra, Ronald
    Lautamaki, Riikka
    Parkkola, Riitta
    Komu, Markku
    Sijens, Paul E.
    Hallsten, Kirstl
    Bergman, Jorgen
    Iozzo, Patricia
    Nuutila, Pirjo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2008, 57 (10): : 1445 - 1451
  • [15] Statin therapy and related risk of new-onset type 2 diabetes mellitus
    Ruscica, Massimiliano
    Macchi, Chiara
    Morlotti, Beatrice
    Sirtori, Cesare R.
    Magni, Paolo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 401 - 406
  • [16] Risk of type 2 diabetes mellitus associated with statin therapy: evidence and possible mechanisms
    Suazo, Jose
    Rigotti, Attilio
    REVISTA MEDICA DE CHILE, 2014, 142 (02) : 222 - 228
  • [17] Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
    Udell, Jacob A.
    Scirica, Benjamin M.
    Braunwald, Eugene
    Raz, Itamar
    Steg, Ph. Gabriel
    Davidson, Jaime
    Hirshberg, Boaz
    Bhatt, Deepak L.
    CLINICAL CARDIOLOGY, 2012, 35 (12) : 722 - 729
  • [18] STATIN THERAPY FOR DYSLIPIDEMIA AND CORONARY HEART DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Cozma, M. A.
    Gaman, M. A.
    Dobrica, E. C.
    Gaman, A. M.
    Diaconu, C. C.
    JOURNAL OF HYPERTENSION, 2019, 37 : E250 - E251
  • [19] Association of Renal Function and Statin Therapy with Lipoprotein(a) in Patients with Type 2 Diabetes
    Hiraishi, Chika
    Matsui, Sadako
    Kojima, Takai
    Sato, Ryo
    Ando, Kiyotaka
    Fujimoto, Kei
    Yoshida, Hiroshi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (01) : 81 - 89
  • [20] Association of Insulin Resistance with Liver Biomarkers in Type 2 Diabetes Mellitus
    Adiga, Usha
    Kathyayani, P.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2019, 9 (01): : 88 - 91